ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”

·4 min read
Precipio, Inc.
Precipio, Inc.

HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting

Precipio receives “New Best Product” Award

Precipio receives “New Best Product” Award
Precipio receives “New Best Product” Award

NEW HAVEN, Conn., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) was recognized at ThermoFisher’s National Sales Meeting for the development and launch of its HemeScreen® technology. HemeScreen is distributed by Fisher Healthcare, a division of ThermoFisher, to laboratories nationwide.

Precipio receives “New Best Product” Award
Precipio receives “New Best Product” Award

Precipio entered into a distribution agreement with Fisher Healthcare in the latter part of 2022 to distribute its Hemescreen products to laboratories. The salesforce enthusiasm and customer engagement accompanying this award is expected to generate orders from Fisher customers in Q2-2023 and rapidly growing revenues in Q3-2023 and beyond.

Of the thousands of products ThermoFisher distributes, Precipio’s HemeScreen was selected as #1 for Best New Product based on various criteria, including:

  • Provides the highest value to customers (clinical impact, workflow simplification, and economic contribution)

  • Represents the highest level of innovation and creativity

  • Will be most attractive to customers and therefore generate significant revenue growth to the sales team

  • Generates the most excitement among their sales team

“We are privileged to have Fisher Healthcare as a distribution partner, and I am honored that our team and our technology has been recognized by such a market leader”, said Ilan Danieli, Precipio’s CEO. “Our company will continue to be entirely focused on translating this positive energy, enthusiasm, and customer interest into revenue and growth for Fisher and for our company, and to delivering the promise of HemeScreen technology to patients nationwide.”

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit

Please follow us on LinkedIn, Twitter @PrecipioDx and on Facebook.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated from time to time in the company’s Securities and Exchange Commission filings.

The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

A photo accompanying this announcement is available at

CONTACT: Inquiries: +1-203-787-7888 Ext. 523